%0 Journal Article %T Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review %A Andr¨¦ D Sasse %A Elisa Sasse %A Albertina M Carvalho %A Ligia T Macedo %J BMC Cancer %D 2012 %I BioMed Central %R 10.1186/1471-2407-12-54 %X Databases (MEDLINE, EMBASE, LILACS, Cochrane databases and ClinicalTrials.gov) were scanned for randomised clinical trials involving radiotherapy with or without androgen suppression in local prostate cancer. The search strategy included articles published until October 2011. The studies were examined and the data of interest were plotted for meta-analysis. Survival outcomes were reported as a hazard ratio with corresponding 95% confidence intervals.Data from ten trials published from 1988 to 2011 were included, comprising 6555 patients. There was a statistically significant advantage to the use of androgen suppression, in terms of both overall survival and disease free survival, when compared to radiotherapy alone. The use of long-term goserelin (up to three years) was the strategy providing the higher magnitude of clinical benefit. In contrast to goserelin, there were no trials evaluating the use of other luteinizing hormone-releasing hormone (LHRH) analogues as monotherapy. Complete hormonal blockade was not shown to be superior to goserelin monotherapy.Based on the findings of this systematic review, the evidence supports the use of androgen suppression with goserelin monotherapy as the standard treatment for patients with prostate cancer treated with radiotherapy, which are at high risk of recurrence or metastases.Prostate cancer is the second most prevalent neoplasm and the sixth leading cause of cancer mortality, with an estimated incidence of 903,500 new cases and 258,400 deaths in 2008 [1]. Historically, the incidence of this condition had a rapid increase during the early 1990s with later stabilization. This can be largely explained by the introduction of prostate specific antigen (PSA) testing, causing a sudden diagnosis boost worldwide. For the same reason, the distribution of prostate cancer cases was heterogeneous, with higher rates observed in the United States, Australia, Norway, Japan, Italy and others [2]. On the other hand, mortality has been decl %U http://www.biomedcentral.com/1471-2407/12/54